ARTV vs CRBU
ARTV: Artiva Biotherapeutics is developing off-the-shelf, allogeneic NK cell therapies designed to address B-cell driven autoimmune diseases through enhanced antibody-dependent cellular cytotoxicity. CRBU: A clinical-stage CRISPR genome-editing company developing off-the-shelf allogeneic CAR-T cell therapies for hematologic cancers.
Side-by-side fundamentals
| Metric | ARTV | CRBU | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $6.49 | $0.5444 | |
| Market cap | $317M | $58M | |
| Net margin FY2025, SEC XBRL | n/a | -1327.4% | |
| Operating margin FY2025, SEC XBRL | n/a | -1329.4% | |
| ROE FY2025, SEC XBRL | -76.3% | -121.2% | ARTV higher |
| ROA FY2025, SEC XBRL | -64.0% | -84.5% | ARTV higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +11.7% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -7.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.57 | 1.76 | |
| 1-year return as of 2026-10-21 close | +48.9% | -80.8% | ARTV higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.